Gapping up
In reaction to strong earnings/guidance:
- DKS +18.8%, MOV +10%, SPTN +4.9%, CRM +4.7%, CVCO +3.7%, HPQ +2.9%, CMCO +2.1%, SB +1.6%, NOAH +0.8%, BMO +0.7%
Other news:
- CVNA +4.6% (light volume; files for offering of 744,037 shares of Class A common stock by holders)
- LPG +3.8% (continued strength after confirming that it has received an unsolicited proposal from BW LPG to combine with Dorian)
- LGCY +2.7% (10% owner Baines Creek disclosed the purchase of 80K shares worth ~$445K)
- SAGE +1.5% (FDA has accepted the filing of a NDA for its lead product candidate, an intravenous formulation of brexanolone (SAGE-547))
- EXEL +1.3% (FDA accepts supplemental New Drug Application for CABOMETYX)
- NVS +0.9% (FDA expedites review of Novartis drug Promacta for first-line severe aplastic anemia)
Analyst comments:
- TDC +2.9% (upgraded to Buy from Neutral at Mizuho)
- ATI +1.3% (upgraded to Neutral from Sell at Goldman)
- XOM +1.1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- TGT +0.7% (added to US 1 List at BofA/Merrill)
![]()